PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature.
Stijn MuselaersSelcuk ErdemRiccardo BertoloAlexandre IngelsÖnder KaraNicola PavanEduard RousselAngela PecoraroMichele MarchioniUmberto CarbonaraLaura MarandinoDaniele AmparoreRiccardo Campinull On Behalf Of The European Association Of Urology Eau Young Academic Urologists Yau Renal Cancer Working GroupPublished in: Journal of clinical medicine (2022)
Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.
Keyphrases
- pet ct
- positron emission tomography
- renal cell carcinoma
- pet imaging
- prostate cancer
- computed tomography
- cell surface
- end stage renal disease
- ejection fraction
- radical prostatectomy
- newly diagnosed
- high resolution
- systematic review
- lymph node
- prognostic factors
- magnetic resonance
- photodynamic therapy
- benign prostatic hyperplasia
- dual energy